{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:04:00Z","timestamp":1794953040331,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Ameliorating symptoms and signs of Huntington\u2019s disease (HD) is essential to care but can be challenging and hard to achieve. The pharmacological treatment of motor signs (e.g. chorea) may favorably or unfavorably impact other facets of the disease phenotype (such as mood and cognition). Similarly, pharmacotherapy for behavioral issues may modify the motor phenotype. Sometimes synergistic effects can be achieved. In patients undergoing pragmatic polypharmacological therapy, emerging complaints may stem from the employed medications' side effects, a possibility that needs to be considered. It is recommended to clearly and precisely delineate the targeted signs and symptoms (e.g., chorea, myoclonus, bradykinesia, Parkinsonism, or dystonia). Evidence from randomized controlled trials (RCTs) is limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary or definition of the topic<\/jats:title>\n                <jats:p>Therefore, the guidelines prepared for the German Neurological Society (DGN) for German-speaking countries intentionally extend beyond evidence from RCTs and aim to synthesize evidence from RCTs and recommendations of experienced clinicians.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recommendations<\/jats:title>\n                <jats:p>First-line treatment for chorea is critically discussed, and a preference in prescription practice for using tiapride instead of tetrabenazine is noted. In severe chorea, combining two antidopaminergic drugs with a postsynaptic (e.g., tiapride) and presynaptic mode of action (e.g., tetrabenazine) is discussed as a potentially helpful strategy. Sedative side effects of both classes of compounds can be used to improve sleep if the highest dosage of the day is given at night. Risperidone, in some cases, may ameliorate irritability but also chorea and sleep disorders. Olanzapine can be helpful in the treatment of weight loss and chorea, and quetiapine as a mood stabilizer with an antidepressant effect.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Since most HD patients simultaneously suffer from distinct motor signs and distinct psychiatric\/behavioral symptoms, treatment should be individually adapted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42466-023-00285-1","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:02:46Z","timestamp":1700092966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Symptomatic treatment options for Huntington\u2019s disease (guidelines of the German Neurological Society)"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-7292","authenticated-orcid":false,"given":"Carsten","family":"Saft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Burgunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Dose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Heinrich","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Katzenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huu Phuc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Reetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Reilmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg Bernhard","family":"Landwehrmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"285_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/NSS.S78947","volume":"8","author":"SM Abbott","year":"2016","unstructured":"Abbott, S. M., & Videnovic, A. (2016). Chronic sleep disturbance and neural injury: Links to neurodegenerative disease. Nature and Science of Sleep, 8, 55\u201361. https:\/\/doi.org\/10.2147\/NSS.S78947","journal-title":"Nature and Science of Sleep"},{"issue":"3","key":"285_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.rpsm.2018.09.002","volume":"12","author":"C Alamo","year":"2019","unstructured":"Alamo, C., Garcia-Garcia, P., Lopez-Munoz, F., & Zaragoza, C. (2019). Tianeptine, an atypical pharmacological approach to depression. Revista de Psiquiatr\u00eda y Salud Mental (English Edition), 12(3), 170\u2013186. https:\/\/doi.org\/10.1016\/j.rpsm.2018.09.002","journal-title":"Revista de Psiquiatr\u00eda y Salud Mental (English Edition)"},{"issue":"3","key":"285_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JHD-180293","volume":"7","author":"KE Anderson","year":"2018","unstructured":"Anderson, K. E., van Duijn, E., Craufurd, D., Drazinic, C., Edmondson, M., Goodman, N., Van Kammen, D., Loy, C., Priller, J., & Goodman, L. V. (2018). Clinical management of neuropsychiatric symptoms of huntington disease: Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders. Journal of Huntington\u2019s Disease, 7(3), 355\u2013366. https:\/\/doi.org\/10.3233\/JHD-180293","journal-title":"Journal of Huntington's Disease"},{"issue":"12","key":"285_CR4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00702-009-0310-1","volume":"116","author":"JE Andrich","year":"2009","unstructured":"Andrich, J. E., Wobben, M., Klotz, P., Goetze, O., & Saft, C. (2009). Upper gastrointestinal findings in Huntington\u2019s disease: Patients suffer but do not complain. Journal of Neural Transmission (Vienna), 116(12), 1607\u20131611. https:\/\/doi.org\/10.1007\/s00702-009-0310-1","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"6","key":"285_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong, M. J., Miyasaki, J. M., & Neurology, A. A. (2012). Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease report of the guideline development subcommittee of the American Academy of Neurology. Neurology, 79(6), 597\u2013603. https:\/\/doi.org\/10.1212\/WNL.0b013e318263c443","journal-title":"Neurology"},{"key":"285_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"AC Bachoud-Levi","year":"2019","unstructured":"Bachoud-Levi, A. C., Ferreira, J., Massart, R., Youssov, K., Rosser, A., Busse, M., Craufurd, D., Reilmann, R., De Michele, G., Rae, D., Squitieri, F., & Burgunder, J. M. (2019). International guidelines for the treatment of Huntington\u2019s disease. Frontiers in Neurology, 10, 710. https:\/\/doi.org\/10.3389\/fneur.2019.00710","journal-title":"Frontiers in Neurology"},{"issue":"01","key":"285_CR7","first-page":"1","volume":"40","author":"C Boch","year":"2012","unstructured":"Boch, C. (2012). Basale stimulation bei Huntington-Kranken. Die Schwester\/Der Pfleger, 40(01), 1\u20136.","journal-title":"Die Schwester\/Der Pfleger"},{"issue":"2","key":"285_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1468-1331.2012.03760.x","volume":"20","author":"S Bohlen","year":"2013","unstructured":"Bohlen, S., Ekwall, C., Hellstrom, K., Vesterlin, H., Bjornefur, M., Wiklund, L., & Reilmann, R. (2013). Physical therapy in Huntington\u2019s disease\u2013toward objective assessments? European Journal of Neurology, 20(2), 389\u2013393. https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03760.x","journal-title":"European Journal of Neurology"},{"issue":"2","key":"285_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/14656566.8.2.141","volume":"8","author":"RM Bonelli","year":"2007","unstructured":"Bonelli, R. M., & Hofmann, P. (2007). A systematic review of the treatment studies in Huntington\u2019s disease since 1990. Expert Opinion on Pharmacotherapy, 8(2), 141\u2013153. https:\/\/doi.org\/10.1517\/14656566.8.2.141","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"21","key":"285_CR10","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2174\/138161206777698693","volume":"12","author":"RM Bonelli","year":"2006","unstructured":"Bonelli, R. M., & Wenning, G. K. (2006). Pharmacological management of Huntington\u2019s disease: An evidence-based review. Current Pharmaceutical Design, 12(21), 2701\u20132720.","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"285_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/mds.22376","volume":"24","author":"L Brusa","year":"2009","unstructured":"Brusa, L., Orlacchio, A., Moschella, V., Iani, C., Bernardi, G., & Mercuri, N. B. (2009). Treatment of the symptoms of Huntington\u2019s disease: Preliminary results comparing aripiprazole and tetrabenazine. Movement Disorders, 24(1), 126\u2013129. https:\/\/doi.org\/10.1002\/mds.22376","journal-title":"Movement Disorders"},{"issue":"1","key":"285_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-190384","volume":"9","author":"E Burnip","year":"2020","unstructured":"Burnip, E., Wallace, E., Gozdzikowska, K., & Huckabee, M. L. (2020). A systematic review of rehabilitation for corticobulbar symptoms in adults with Huntington\u2019s disease. Journal of Huntington\u2019s Disease, 9(1), 1\u201312. https:\/\/doi.org\/10.3233\/JHD-190384","journal-title":"Journal of Huntington's Disease"},{"key":"285_CR13","doi-asserted-by":"publisher","first-page":"A62","DOI":"10.1136\/jnnp-2012-303524.193","volume":"83","author":"JG Caldentey","year":"2012","unstructured":"Caldentey, J. G., Lopez-Sendon, J. L., Trigo, P., Ruiz, C., Ribas, G. G., Aguilar, M., Galvez, M. A., Pablo, I., Galve-Roth, I., Sagredo, O., Fernandez-Ruiz, J. J., & Garcia, J. (2012). A double blind, cross over, placebo-controlled, phase II trial of sativex in Huntington\u2019s disease. Journal of Neurology Neurosurgery and Psychiatry, 83, A62\u2013A62. https:\/\/doi.org\/10.1136\/jnnp-2012-303524.193","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"key":"285_CR14","first-page":"1","volume":"5","author":"A Ciammola","year":"2009","unstructured":"Ciammola, A., Sassone, J., Colciago, C., Mencacci, N. E., Poletti, B., Ciarmiello, A., Squitieri, F., & Silani, V. (2009). Aripiprazole in the treatment of Huntington\u2019s disease: A case series. Neuropsychiatric Disease and Treatment, 5, 1\u20134.","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"3","key":"285_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/mds.870120319","volume":"12","author":"PG Como","year":"1997","unstructured":"Como, P. G., Rubin, A. J., O\u2019Brien, C. F., Lawler, K., Hickey, C., Rubin, A. E., Henderson, R., McDermott, M. P., McDermott, M., Steinberg, K., & Shoulson, I. (1997). A controlled trial of fluoxetine in nondepressed patients with Huntington\u2019s disease. Movement Disorders, 12(3), 397\u2013401. https:\/\/doi.org\/10.1002\/mds.870120319","journal-title":"Movement Disorders"},{"issue":"15","key":"285_CR16","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/mds.22809","volume":"24","author":"A Curtis","year":"2009","unstructured":"Curtis, A., Mitchell, I., Patel, S., Ives, N., & Rickards, H. (2009). A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease. Movement Disorders, 24(15), 2254\u20132259. https:\/\/doi.org\/10.1002\/mds.22809","journal-title":"Movement Disorders"},{"key":"285_CR17","first-page":"S368","volume":"33","author":"M Delnomdedieu","year":"2018","unstructured":"Delnomdedieu, M., Tan, Y., Ogde, A., Berger, Z., & Reilmann, R. (2018). A randomized, double-blind, placebo-controlled phase II efficacy and safety study of the PDE10A inhibitor PF-02545920 in Huntington disease (AMARYLLIS). Movement Disorders, 33, S368\u2013S368.","journal-title":"Movement Disorders"},{"issue":"8\u20139","key":"285_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neurol.2016.07.012","volume":"172","author":"G Desamericq","year":"2016","unstructured":"Desamericq, G., Youssov, K., Charles, P., Saleh, N., Olivier, A., Sherer-Gagou, C., Verny, C., & Bachoud-Levi, A. C. (2016). Guidelines for clinical pharmacological practices in Huntington\u2019s disease. Revue Neurologique (Paris), 172(8\u20139), 423\u2013432. https:\/\/doi.org\/10.1016\/j.neurol.2016.07.012","journal-title":"Revue Neurologique (Paris)"},{"issue":"10","key":"285_CR19","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/mds.26308","volume":"30","author":"JJ Ferreira","year":"2015","unstructured":"Ferreira, J. J., Rosser, A., Craufurd, D., Squitieri, F., Mallard, N., & Landwehrmeyer, B. (2015). Ethyl-eicosapentaenoic acid treatment in Huntington\u2019s disease: A placebo-controlled clinical trial. Movement Disorders, 30(10), 1426\u20131429. https:\/\/doi.org\/10.1002\/mds.26308","journal-title":"Movement Disorders"},{"issue":"4","key":"285_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3233\/JHD-140127","volume":"3","author":"CA Fisher","year":"2014","unstructured":"Fisher, C. A., Sewell, K., Brown, A., & Churchyard, A. (2014). Aggression in Huntington\u2019s disease: A systematic review of rates of aggression and treatment methods. Journal of Huntington\u2019s Disease, 3(4), 319\u2013332. https:\/\/doi.org\/10.3233\/JHD-140127","journal-title":"Journal of Huntington's Disease"},{"issue":"1","key":"285_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00415-016-8310-1","volume":"264","author":"S Frese","year":"2017","unstructured":"Frese, S., Petersen, J. A., Ligon-Auer, M., Mueller, S. M., Mihaylova, V., Gehrig, S. M., Kana, V., Rushing, E. J., Unterburger, E., K\u00e4gi, G., Burgunder, J. M., & Jung, H. H. (2017). Exercise effects in Huntington disease. Journal of Neurology, 264(1), 32\u201339. https:\/\/doi.org\/10.1007\/s00415-016-8310-1","journal-title":"Journal of Neurology"},{"issue":"3","key":"285_CR22","doi-asserted-by":"publisher","first-page":"e0173872","DOI":"10.1371\/journal.pone.0173872","volume":"12","author":"H Gelderblom","year":"2017","unstructured":"Gelderblom, H., Wustenberg, T., McLean, T., Mutze, L., Fischer, W., Saft, C., Hoffmann, R., S\u00fcssmuth, S., Schlattmann, P., Van Duijn, E., Landwehrmeyer, B., & Priller, J. (2017). Bupropion for the treatment of apathy in Huntington\u2019s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE, 12(3), e0173872. https:\/\/doi.org\/10.1371\/journal.pone.0173872","journal-title":"PLoS ONE"},{"issue":"2","key":"285_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/1460-6984.12604","volume":"56","author":"TN Grimstvedt","year":"2021","unstructured":"Grimstvedt, T. N., Miller, J. U., van Walsem, M. R., & Feragen, K. J. B. (2021). Speech and language difficulties in Huntington\u2019s disease: A qualitative study of patients\u2019 and professional caregivers\u2019 experiences. International Journal of Language & Communication Disorders, 56(2), 330\u2013345. https:\/\/doi.org\/10.1111\/1460-6984.12604","journal-title":"International Journal of Language & Communication Disorders"},{"issue":"1","key":"285_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamaneurol.382","volume":"70","author":"Group, H. I. o. t. H. S., & European Huntington's Disease, N","year":"2013","unstructured":"Group, H. I. o. t. H. S., & European Huntington\u2019s Disease, N. (2013). A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. Jama Neurology, 70(1), 25\u201333. https:\/\/doi.org\/10.1001\/2013.jamaneurol.382","journal-title":"Jama Neurology"},{"key":"285_CR25","doi-asserted-by":"publisher","DOI":"10.7916\/tohm.v0.701","author":"J Ha","year":"2019","unstructured":"Ha, J., Na, B. S., Ahn, J. H., Kim, M., Kim, J. W., Lee, J. H., Cho, J. W., Kim, J. S., & Youn, J. (2019). Anti-CV2\/CRMP5 paraneoplastic chorea effectively managed with intravenous amantadine. Tremor and Other Hyperkinetic Movements (New York, NY). https:\/\/doi.org\/10.7916\/tohm.v0.701","journal-title":"Tremor and Other Hyperkinetic Movements (New York, NY)"},{"issue":"6","key":"285_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/jnnp-2019-322038","volume":"91","author":"KL Harris","year":"2020","unstructured":"Harris, K. L., Kuan, W. L., Mason, S. L., & Barker, R. A. (2020). Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington\u2019s disease (Enroll-HD). Journal of Neurology, Neurosurgery and Psychiatry, 91(6), 622\u2013630. https:\/\/doi.org\/10.1136\/jnnp-2019-322038","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"3","key":"285_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ddrr.119","volume":"16","author":"F Hassler","year":"2010","unstructured":"Hassler, F., & Reis, O. (2010). Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature. Developmental Disabilities Research Reviews, 16(3), 265\u2013272. https:\/\/doi.org\/10.1002\/ddrr.119","journal-title":"Developmental Disabilities Research Reviews"},{"issue":"1","key":"285_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00455-010-9302-4","volume":"26","author":"AW Heemskerk","year":"2011","unstructured":"Heemskerk, A. W., & Roos, R. A. (2011). Dysphagia in Huntington\u2019s disease: A review. Dysphagia, 26(1), 62\u201366. https:\/\/doi.org\/10.1007\/s00455-010-9302-4","journal-title":"Dysphagia"},{"issue":"1","key":"285_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","volume":"25","author":"AK Holl","year":"2010","unstructured":"Holl, A. K., Wilkinson, L., Painold, A., Holl, E. M., & Bonelli, R. M. (2010). Combating depression in Huntington\u2019s disease: Effective antidepressive treatment with venlafaxine XR. International Clinical Psychopharmacology, 25(1), 46\u201350. https:\/\/doi.org\/10.1097\/YIC.0b013e3283348018","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"285_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study, G","year":"2006","unstructured":"Huntington Study, G. (2006). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology, 66(3), 366\u2013372. https:\/\/doi.org\/10.1212\/01.wnl.0000198586.85250.13","journal-title":"Neurology"},{"key":"285_CR31","doi-asserted-by":"publisher","unstructured":"Huntington Study, G., Frank, S., Testa, C. M., Stamler, D., Kayson, E., Davis, C., et al.. (2016). Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. JAMA, 316(1), 40\u201350. https:\/\/doi.org\/10.1001\/jama.2016.8655","DOI":"10.1001\/jama.2016.8655"},{"issue":"2","key":"285_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/YIC.0b013e3283407775","volume":"26","author":"TG Johnston","year":"2011","unstructured":"Johnston, T. G. (2011). Risperidone long-acting injection and Huntington\u2019s disease: Case series with significant psychiatric and behavioural symptoms. International Clinical Psychopharmacology, 26(2), 114\u2013119. https:\/\/doi.org\/10.1097\/YIC.0b013e3283407775","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"285_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/ggi.13202","volume":"18","author":"MJ Kang","year":"2018","unstructured":"Kang, M. J., Suh, J., Kim, S., & Park, Y. H. (2018). Cyproterone acetate as a treatment for moderate-to-severe inappropriate sexual behavior in dementia. Geriatrics & Gerontology International, 18(2), 366\u2013368. https:\/\/doi.org\/10.1111\/ggi.13202","journal-title":"Geriatrics & Gerontology International"},{"issue":"2","key":"285_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3233\/JHD-190390","volume":"9","author":"M Keage","year":"2020","unstructured":"Keage, M., Baum, S., Pointon, L., Lau, J., Berndt, J., Hopkins, J., Maule, R., & Vogel, A. P. (2020). Imaging and clinical data on swallowing function of individuals with Huntington\u2019s disease and dysphagia. Journal of Huntington\u2019s Disease, 9(2), 163\u2013171. https:\/\/doi.org\/10.3233\/JHD-190390","journal-title":"Journal of Huntington's Disease"},{"issue":"1","key":"285_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mds.21161","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney, C., Hunter, C., Davidson, A., & Jankovic, J. (2007). Short-term effects of tetrabenazine on chorea associated with Huntington\u2019s disease. Movement Disorders, 22(1), 10\u201313. https:\/\/doi.org\/10.1002\/mds.21161","journal-title":"Movement Disorders"},{"issue":"2","key":"285_CR36","doi-asserted-by":"publisher","first-page":"CD007989","DOI":"10.1002\/14651858.CD007989.pub2","volume":"2015","author":"O Khan","year":"2015","unstructured":"Khan, O., Ferriter, M., Huband, N., Powney, M. J., Dennis, J. A., & Duggan, C. (2015). Pharmacological interventions for those who have sexually offended or are at risk of offending. Cochrane Database Systematic Review, 2015(2), CD007989. https:\/\/doi.org\/10.1002\/14651858.CD007989.pub2","journal-title":"Cochrane Database Systematic Review"},{"key":"285_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11940-012-0165-x","volume":"14","author":"A Killoran","year":"2012","unstructured":"Killoran, A., & Biglan, K. M. (2012). Therapeutics in Huntington\u2019s Disease. Current Treatment Options in Neurology, 14, 137\u2013149. https:\/\/doi.org\/10.1007\/s11940-012-0165-x","journal-title":"Current Treatment Options in Neurology"},{"issue":"11","key":"285_CR38","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/mds.26014","volume":"29","author":"A Killoran","year":"2014","unstructured":"Killoran, A., & Biglan, K. M. (2014). Current therapeutic options for Huntington\u2019s disease: Good clinical practice versus evidence-based approaches? Movement Disorders, 29(11), 1404\u20131413. https:\/\/doi.org\/10.1002\/mds.26014","journal-title":"Movement Disorders"},{"issue":"9","key":"285_CR39","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/14737175.2022.2091988","volume":"22","author":"T Kinfe","year":"2022","unstructured":"Kinfe, T., Del Vecchio, A., Nussel, M., Zhao, Y., Stadlbauer, A., & Buchfelder, M. (2022). Deep brain stimulation and stereotactic-assisted brain graft injection targeting fronto-striatal circuits for Huntington\u2019s disease: An update. Expert Review of Neurotherapeutics, 22(9), 781\u2013788. https:\/\/doi.org\/10.1080\/14737175.2022.2091988","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"8","key":"285_CR40","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/archneur.1988.00520320068017","volume":"45","author":"DJ Lanska","year":"1988","unstructured":"Lanska, D. J., Lanska, M. J., Lavine, L., & Schoenberg, B. S. (1988). Conditions associated with Huntington\u2019s disease at death. A case-control study. Archives of Neurology, 45(8), 878\u2013880. https:\/\/doi.org\/10.1001\/archneur.1988.00520320068017","journal-title":"Archives of Neurology"},{"issue":"2","key":"285_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/00048677509159834","volume":"9","author":"DP Leonard","year":"1975","unstructured":"Leonard, D. P., Kidson, M. A., Brown, J. G., Shannon, P. J., & Taryan, S. (1975). A double blind trial of lithium carbonate and haloperidol in Huntington\u2019s chorea. Australian and New Zealand Journal of Psychiatry, 9(2), 115\u2013118. https:\/\/doi.org\/10.3109\/00048677509159834","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"285_CR42","doi-asserted-by":"publisher","first-page":"CD009444","DOI":"10.1002\/14651858.CD009444.pub3","volume":"3","author":"Y Li","year":"2015","unstructured":"Li, Y., Hai, S., Zhou, Y., & Dong, B. R. (2015). Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database of Systematic Reviews, 3, CD009444. https:\/\/doi.org\/10.1002\/14651858.CD009444.pub3","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"285_CR43","doi-asserted-by":"publisher","first-page":"CD006455","DOI":"10.1002\/14651858.CD006455.pub2","volume":"3","author":"T Mestre","year":"2009","unstructured":"Mestre, T., Ferreira, J., Coelho, M. M., Rosa, M., & Sampaio, C. (2009). Therapeutic interventions for disease progression in Huntington\u2019s disease. Cochrane Database of Systematic Reviews, 3, CD006455. https:\/\/doi.org\/10.1002\/14651858.CD006455.pub2","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"285_CR44","doi-asserted-by":"publisher","first-page":"CD006456","DOI":"10.1002\/14651858.CD006456.pub2","volume":"3","author":"T Mestre","year":"2009","unstructured":"Mestre, T., Ferreira, J., Coelho, M. M., Rosa, M., & Sampaio, C. (2009). Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database of Systematic Reviews, 3, CD006456. https:\/\/doi.org\/10.1002\/14651858.CD006456.pub2","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"285_CR45","doi-asserted-by":"publisher","first-page":"825532","DOI":"10.3389\/fpsyt.2021.825532","volume":"12","author":"MJ Molnar","year":"2021","unstructured":"Molnar, M. J., Molnar, V., Fedor, M., Csehi, R., Acsai, K., Borsos, B., & Grosz, Z. (2021). Improving mood and cognitive symptoms in Huntington\u2019s disease with cariprazine treatment. Frontiers in Psychiatry, 12, 825532. https:\/\/doi.org\/10.3389\/fpsyt.2021.825532","journal-title":"Frontiers in Psychiatry"},{"issue":"7","key":"285_CR46","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"JLLS Moreno","year":"2016","unstructured":"Moreno, J. L. L. S., Caldentey, J. G., Cubillo, P. T., Romero, C. R., Ribas, G. G., Arias, M. A. A. A., Garc\u00eda de Y\u00e9benes, M. J., Tol\u00f3n, R. M., Galve-Roperh, I., Sagredo, O., Valdeolivas, S., & Prous, J. G. D. (2016). A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. Journal of Neurology, 263(7), 1390\u20131400. https:\/\/doi.org\/10.1007\/s00415-016-8145-9","journal-title":"Journal of Neurology"},{"issue":"7","key":"285_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.parkreldis.2006.08.005","volume":"13","author":"WG Ondo","year":"2007","unstructured":"Ondo, W. G., Mejia, N. I., & Hunter, C. B. (2007). A pilot study of the clinical efficacy and safety of memantine for Huntington\u2019s disease. Parkinsonism & Related Disorders, 13(7), 453\u2013454. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.08.005","journal-title":"Parkinsonism & Related Disorders"},{"issue":"5","key":"285_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1212\/WNL.0000000000008887","volume":"94","author":"L Quinn","year":"2020","unstructured":"Quinn, L., Kegelmeyer, D., Kloos, A., Rao, A. K., Busse, M., & Fritz, N. E. (2020). Clinical recommendations to guide physical therapy practice for Huntington disease. Neurology, 94(5), 217\u2013228. https:\/\/doi.org\/10.1212\/WNL.0000000000008887","journal-title":"Neurology"},{"issue":"6","key":"285_CR49","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/mdc3.13002","volume":"7","author":"D Richter","year":"2020","unstructured":"Richter, D., Saft, C., & Tonges, L. (2020). Emergence of Bruxism after reducing left pallidal stimulation in a patient with Huntington\u2019s disease. Movement Disorders Clinical Practice, 7(6), 704\u2013705. https:\/\/doi.org\/10.1002\/mdc3.13002","journal-title":"Movement Disorders Clinical Practice"},{"issue":"6","key":"285_CR50","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00115-015-4306-9","volume":"86","author":"JD Rollnik","year":"2015","unstructured":"Rollnik, J. D. (2015). Huntington\u2019s disease. Der Nervenarzt, 86(6), 725\u2013735. https:\/\/doi.org\/10.1007\/s00115-015-4306-9","journal-title":"Der Nervenarzt"},{"issue":"2","key":"285_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.31887\/DCNS.2007.9.2\/arosenblatt","volume":"9","author":"A Rosenblatt","year":"2007","unstructured":"Rosenblatt, A. (2007). Neuropsychiatry of Huntington\u2019s disease. Dialogues in Clinical Neuroscience, 9(2), 191\u2013197. https:\/\/doi.org\/10.31887\/DCNS.2007.9.2\/arosenblatt","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"285_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1471-2377-13-114","volume":"13","author":"C Saft","year":"2013","unstructured":"Saft, C., Andrich, J. E., Muller, T., Becker, J., & Jackowski, J. (2013). Oral and dental health in Huntington\u2019s disease\u2014An observational study. BMC Neurology, 13, 114. https:\/\/doi.org\/10.1186\/1471-2377-13-114","journal-title":"BMC Neurology"},{"key":"285_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2377-6-11","volume":"6","author":"C Saft","year":"2006","unstructured":"Saft, C., Lauter, T., Kraus, P. H., Przuntek, H., & Andrich, J. E. (2006). Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington\u2019s Disease patients: A case series. BMC Neurology, 6, 11.","journal-title":"BMC Neurology"},{"issue":"2","key":"285_CR54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JHD-170283","volume":"7","author":"C Saft","year":"2018","unstructured":"Saft, C., von Hein, S. M., Lucke, T., Thiels, C., Peball, M., Djamshidian, A., Heim, B., & Seppi, K. (2018). Cannabinoids for treatment of dystonia in Huntington\u2019s disease. Journal of Huntington\u2019s Disease, 7(2), 167\u2013173. https:\/\/doi.org\/10.3233\/JHD-170283","journal-title":"Journal of Huntington's Disease"},{"issue":"9","key":"285_CR55","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1111\/ene.14953","volume":"28","author":"B Schumann-Werner","year":"2021","unstructured":"Schumann-Werner, B., Dogan, I., Mirzazade, S., Mall, B., Overbeck, R., Honrath, P., Schulz, J. B., Reetz, K., & Werner, C. J. (2021). Clinical predictors and neural correlates for compromised swallowing safety in Huntington disease. European Journal of Neurology, 28(9), 2855\u20132862. https:\/\/doi.org\/10.1111\/ene.14953","journal-title":"European Journal of Neurology"},{"issue":"2","key":"285_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/15622970701332520","volume":"9","author":"YC Shen","year":"2008","unstructured":"Shen, Y. C. (2008). Lamotrigine in motor and mood symptoms of Huntington\u2019s disease. The World Journal of Biological Psychiatry, 9(2), 147\u2013149. https:\/\/doi.org\/10.1080\/15622970701332520","journal-title":"The World Journal of Biological Psychiatry"},{"issue":"7","key":"285_CR57","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., Johnson, H., Craufurd, D., & Langbehn, D. R. (2013). Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: Analysis of 36-month observational data. The Lancet Neurology, 12(7), 637\u2013649.","journal-title":"The Lancet Neurology"},{"issue":"8","key":"285_CR58","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1176\/ajp.150.8.1274c","volume":"150","author":"AR Torres","year":"1993","unstructured":"Torres, A. R., & Cerqueira, A. T. (1993). Exhibitionism treated with clomipramine. American Journal of Psychiatry, 150(8), 1274. https:\/\/doi.org\/10.1176\/ajp.150.8.1274c","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"285_CR59","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11940-010-0088-3","volume":"12","author":"E van Duijn","year":"2010","unstructured":"van Duijn, E. (2010). Treatment of Irritability in Huntington\u2019s Disease. Current Treatment Options in Neurology, 12(5), 424\u2013433. https:\/\/doi.org\/10.1007\/s11940-010-0088-3","journal-title":"Current Treatment Options in Neurology"},{"key":"285_CR60","doi-asserted-by":"publisher","unstructured":"van Duijn, E., Craufurd, D., Hubers, A. A., Giltay, E. J., Bonelli, R., Rickards, H., . . . European Huntington's Disease Network Behavioural Phenotype Working, G. (2014). Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). Journal of Neurology, Neurosurgery & Psychiatry, 85(12), 1411\u20131418. https:\/\/doi.org\/10.1136\/jnnp-2013-307343","DOI":"10.1136\/jnnp-2013-307343"},{"issue":"6","key":"285_CR61","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2217\/nmt.15.45","volume":"5","author":"DJ van Wamelen","year":"2015","unstructured":"van Wamelen, D. J., Roos, R. A., & Aziz, N. A. (2015). Therapeutic strategies for circadian rhythm and sleep disturbances in Huntington disease. Neurodegenerative Disease Management, 5(6), 549\u2013559. https:\/\/doi.org\/10.2217\/nmt.15.45","journal-title":"Neurodegenerative Disease Management"},{"issue":"Suppl 1","key":"285_CR62","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1055\/s-2007-1001160","volume":"66","author":"HP Volz","year":"1998","unstructured":"Volz, H. P., & Moller, H. J. (1998). Opipramol in anxiety and somatoform disorders Results of a controlled study. Fortschritte der Neurologie-psychiatrie, 66(Suppl 1), S21-24. https:\/\/doi.org\/10.1055\/s-2007-1001160","journal-title":"Fortschritte der Neurologie-psychiatrie"},{"key":"285_CR63","doi-asserted-by":"publisher","unstructured":"Wojtecki, L., Groiss, S. J., Ferrea, S., Elben, S., Hartmann, C. J., Dunnett, S. B., . . . Surgical Approaches Working Group of the European Huntington's Disease, N. (2015). A prospective pilot trial for pallidal deep brain stimulation in Huntington's disease. Frontiers in Neurology, 6, 177. https:\/\/doi.org\/10.3389\/fneur.2015.00177","DOI":"10.3389\/fneur.2015.00177"},{"issue":"1","key":"285_CR64","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1038\/s41467-018-06675-3","volume":"9","author":"H Zhang","year":"2018","unstructured":"Zhang, H., Zhang, C., Vincent, J., Zala, D., Benstaali, C., Sainlos, M., Grillo-Bosch, D., Daburon, S., Coussen, F., Cho, Y., David, D. J., & Choquet, D. (2018). Modulation of AMPA receptor surface diffusion restores hippocampal plasticity and memory in Huntington\u2019s disease models. Nature Communications, 9(1), 4272. https:\/\/doi.org\/10.1038\/s41467-018-06675-3","journal-title":"Nature Communications"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-023-00285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-023-00285-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-023-00285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:03:32Z","timestamp":1700093012000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-023-00285-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1186\/s42466-023-00285-1","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"18 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Given by all authors and the German Neurological society.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests with regard to the contents (see attached CoI-satement. A detailed listing is available at .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}